Regen BioPharma, Inc. (RGBP)

Regen BioPharma Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Net Income	-1.13	-0.87	1.16	2.44	-6.77	3.41
Other Amortization	0.05	0.03	0	0.07	0.05	0.61
Loss (Gain) From Sale of Investments	0.2	0.2	-	-0.03	1.16	-
Stock-Based Compensation	0.16	0.15	0.25	0.05	0	0
Other Operating Activities	-	-	0.35	0	-1.87	-
Change in Accounts Receivable	-0.11	-0.09	0.25	-0.04	-0.11	-0.03
Change in Accounts Payable	0	-0	0	-0.06	-0.02	0.02
Change in Unearned Revenue	-0.13	-0.14	-0.11	-0.13	1.84	-
Change in Other Net Operating Assets	0.47	0.02	-2.07	-2.91	4.59	-3.99
Operating Cash Flow	-0.49	-0.69	-0.17	-0.61	-1.13	0.02
Investment in Securities	-	-	-	0.03	0.5	-
Investing Cash Flow	-	-	-	0.03	0.5	-
Short-Term Debt Issued	-	0.02	0.24	0	1.36	-
Total Debt Issued	0.19	0.02	0.24	0	1.36	-
Short-Term Debt Repaid	-	-	-	-	-	-0.03
Long-Term Debt Repaid	-	-0.01	-	-0.09	-	-
Total Debt Repaid	0.06	-0.01	-	-0.09	-	-0.03
Net Debt Issued (Repaid)	0.25	0.01	0.24	-0.09	1.36	-0.03
Issuance of Common Stock	0.16	0.56	-	-	-	-
Financing Cash Flow	0.41	0.57	0.24	-0.09	1.36	-0.03
Miscellaneous Cash Flow Adjustments	-0	-	-	-0	-	-
Net Cash Flow	-0.08	-0.12	0.07	-0.68	0.73	-0.01
Cash Interest Paid	0.02	0.02	-	0.03	-	-
Levered Free Cash Flow	0.06	-0.41	-2.56	-4.04	5.79	-4.15
Unlevered Free Cash Flow	0.1	-0.38	-2.52	-3.98	5.97	-4.17
Change in Net Working Capital	-0.17	0.27	2.34	3.81	-6.1	4.04

Source: S&P Global Market Intelligence. Standard template. Financial Sources.